Sengenics, a portfolio company of Summa Equity, has been acquired by Standard BioTools to enhance its proteomics offerings in biopharma and translational research.

Target Overview

Sengenics, a company under the ownership of Summa Equity, has been acquired by Standard BioTools. Founded in 2008, Sengenics specializes in functional proteomics, focusing on the detection of autoantibody biomarkers and protein interactions. Its innovative KREX™ protein-folding technology is pivotal for precise antibody profiling, being utilized extensively across its product offerings, including the flagship i-OMETM Discovery platform that houses over 1,800 curated disease-relevant auto-antibody targets.

Industry Overview

The proteomics market is experiencing significant growth, with projections estimating an increase from $31.6 billion in 2024 to $94.7 billion by 2035. Proteomics involves the large-scale study of proteins, essential for understanding cellular functions and disease pathways, thereby playing a critical role in advancing personalized medicine, cancer immunotherapy, and the treatment of autoimmune diseases. As pharmaceutical and biotech companies focus more on complex biological mechanisms for drug discovery and development, the demand for sophisticated proteomic tools and technologies continues to surge.

In this evolving landscape, companies that innovate within the proteomics field are crucial for providing insights that inform drug development and improve patient outcomes. The gro